| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 121 | 2025 | 2567 | 16.460 |
Why?
|
| Polymyxin B | 27 | 2024 | 46 | 9.830 |
Why?
|
| Pseudomonas aeruginosa | 39 | 2023 | 175 | 8.520 |
Why?
|
| Acinetobacter baumannii | 18 | 2025 | 46 | 8.420 |
Why?
|
| Microbial Sensitivity Tests | 75 | 2025 | 848 | 7.120 |
Why?
|
| Acinetobacter Infections | 13 | 2025 | 35 | 6.820 |
Why?
|
| Pseudomonas Infections | 23 | 2023 | 117 | 6.520 |
Why?
|
| Cephalosporins | 20 | 2024 | 137 | 5.280 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 29 | 2024 | 153 | 5.100 |
Why?
|
| Klebsiella pneumoniae | 16 | 2022 | 89 | 4.160 |
Why?
|
| Drug Resistance, Bacterial | 22 | 2017 | 390 | 3.730 |
Why?
|
| Bacteremia | 13 | 2022 | 427 | 3.530 |
Why?
|
| Ceftazidime | 7 | 2025 | 51 | 3.530 |
Why?
|
| Anti-Infective Agents | 18 | 2022 | 265 | 3.390 |
Why?
|
| beta-Lactamase Inhibitors | 9 | 2023 | 65 | 2.950 |
Why?
|
| Minocycline | 6 | 2022 | 44 | 2.880 |
Why?
|
| Klebsiella Infections | 8 | 2022 | 63 | 2.630 |
Why?
|
| Vancomycin | 9 | 2025 | 225 | 2.620 |
Why?
|
| Polymyxins | 8 | 2023 | 15 | 2.580 |
Why?
|
| Gram-Negative Bacterial Infections | 15 | 2019 | 94 | 2.510 |
Why?
|
| Carbapenems | 6 | 2024 | 46 | 2.430 |
Why?
|
| Models, Biological | 21 | 2018 | 1396 | 2.420 |
Why?
|
| beta-Lactamases | 16 | 2023 | 223 | 2.370 |
Why?
|
| Azabicyclo Compounds | 8 | 2025 | 27 | 2.360 |
Why?
|
| Colistin | 9 | 2019 | 30 | 2.330 |
Why?
|
| beta-Lactam Resistance | 8 | 2019 | 49 | 2.200 |
Why?
|
| Amikacin | 8 | 2025 | 25 | 2.140 |
Why?
|
| Kidney | 12 | 2025 | 1304 | 2.050 |
Why?
|
| Aminoglycosides | 9 | 2023 | 47 | 2.050 |
Why?
|
| beta-Lactams | 9 | 2020 | 57 | 2.000 |
Why?
|
| Pneumonia, Bacterial | 8 | 2015 | 79 | 1.990 |
Why?
|
| Gram-Negative Bacteria | 10 | 2023 | 75 | 1.860 |
Why?
|
| Acute Kidney Injury | 6 | 2025 | 690 | 1.790 |
Why?
|
| Tandem Mass Spectrometry | 10 | 2024 | 291 | 1.670 |
Why?
|
| Chromatography, Liquid | 8 | 2020 | 240 | 1.600 |
Why?
|
| Drug Combinations | 8 | 2024 | 280 | 1.490 |
Why?
|
| Quinolines | 5 | 2025 | 121 | 1.460 |
Why?
|
| Thienamycins | 7 | 2017 | 12 | 1.450 |
Why?
|
| Iron | 2 | 2025 | 308 | 1.410 |
Why?
|
| Bacterial Proteins | 11 | 2023 | 940 | 1.410 |
Why?
|
| Kidney Tubules, Proximal | 4 | 2024 | 74 | 1.390 |
Why?
|
| Staphylococcus aureus | 8 | 2024 | 482 | 1.380 |
Why?
|
| Bacterial Infections | 7 | 2019 | 325 | 1.360 |
Why?
|
| Humans | 143 | 2025 | 132158 | 1.290 |
Why?
|
| Hydroxyurea | 3 | 2025 | 88 | 1.270 |
Why?
|
| Renal Insufficiency | 4 | 2016 | 252 | 1.250 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2025 | 1146 | 1.220 |
Why?
|
| Fluoroquinolones | 7 | 2011 | 93 | 1.190 |
Why?
|
| Escherichia coli | 8 | 2019 | 986 | 1.170 |
Why?
|
| Ceftriaxone | 4 | 2020 | 68 | 1.150 |
Why?
|
| Sepsis | 3 | 2023 | 496 | 1.140 |
Why?
|
| Cerebral Ventriculitis | 2 | 2025 | 16 | 1.110 |
Why?
|
| Creatinine | 9 | 2025 | 402 | 1.060 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 3 | 2024 | 19 | 1.060 |
Why?
|
| Models, Theoretical | 11 | 2016 | 366 | 1.040 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2021 | 34 | 1.040 |
Why?
|
| Culture Media | 3 | 2024 | 175 | 0.980 |
Why?
|
| Animals | 49 | 2025 | 34288 | 0.970 |
Why?
|
| Levofloxacin | 6 | 2017 | 50 | 0.950 |
Why?
|
| Ofloxacin | 7 | 2012 | 30 | 0.920 |
Why?
|
| Sulfides | 1 | 2025 | 26 | 0.910 |
Why?
|
| Cyclopropanes | 1 | 2025 | 75 | 0.890 |
Why?
|
| Models, Statistical | 6 | 2014 | 494 | 0.890 |
Why?
|
| Acetates | 1 | 2025 | 81 | 0.890 |
Why?
|
| Microbial Viability | 3 | 2011 | 43 | 0.890 |
Why?
|
| Licensure, Pharmacy | 1 | 2024 | 1 | 0.870 |
Why?
|
| Rats | 15 | 2025 | 3459 | 0.860 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2020 | 1624 | 0.840 |
Why?
|
| Pharmaceutical Preparations | 3 | 2021 | 81 | 0.830 |
Why?
|
| Kidney Diseases | 2 | 2025 | 484 | 0.830 |
Why?
|
| Bacteria | 5 | 2021 | 537 | 0.820 |
Why?
|
| Female | 65 | 2025 | 71430 | 0.800 |
Why?
|
| Education, Pharmacy | 1 | 2024 | 63 | 0.800 |
Why?
|
| Pharmacists | 1 | 2024 | 103 | 0.800 |
Why?
|
| Middle Aged | 41 | 2025 | 28939 | 0.790 |
Why?
|
| Cross Infection | 7 | 2017 | 334 | 0.790 |
Why?
|
| Students, Pharmacy | 1 | 2024 | 76 | 0.780 |
Why?
|
| Moths | 1 | 2023 | 17 | 0.780 |
Why?
|
| Superinfection | 1 | 2022 | 7 | 0.750 |
Why?
|
| Imipenem | 2 | 2012 | 9 | 0.740 |
Why?
|
| Plasma | 3 | 2015 | 103 | 0.730 |
Why?
|
| Aged | 34 | 2025 | 21279 | 0.720 |
Why?
|
| Male | 60 | 2025 | 65464 | 0.720 |
Why?
|
| Pharmacokinetics | 3 | 2006 | 15 | 0.710 |
Why?
|
| Educational Measurement | 1 | 2024 | 318 | 0.710 |
Why?
|
| Piperacillin | 6 | 2019 | 14 | 0.700 |
Why?
|
| Area Under Curve | 8 | 2024 | 322 | 0.680 |
Why?
|
| Lactams | 1 | 2021 | 22 | 0.670 |
Why?
|
| Lung | 8 | 2025 | 1580 | 0.670 |
Why?
|
| Transitional Care | 1 | 2020 | 17 | 0.660 |
Why?
|
| Coinfection | 1 | 2022 | 191 | 0.640 |
Why?
|
| Epithelial Cells | 2 | 2014 | 902 | 0.620 |
Why?
|
| Drug Therapy, Combination | 10 | 2017 | 1171 | 0.620 |
Why?
|
| Mice | 23 | 2025 | 18397 | 0.610 |
Why?
|
| Colony Count, Microbial | 10 | 2009 | 86 | 0.600 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 268 | 0.580 |
Why?
|
| Enterobacteriaceae | 1 | 2019 | 41 | 0.580 |
Why?
|
| Hospitals, University | 4 | 2012 | 103 | 0.550 |
Why?
|
| Blood Proteins | 2 | 2017 | 140 | 0.550 |
Why?
|
| Adult | 32 | 2025 | 31755 | 0.550 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 6924 | 0.550 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2017 | 4 | 0.550 |
Why?
|
| Time Factors | 16 | 2014 | 6288 | 0.540 |
Why?
|
| Infusions, Intravenous | 10 | 2020 | 550 | 0.540 |
Why?
|
| Administration, Intravenous | 5 | 2022 | 171 | 0.540 |
Why?
|
| Drug Utilization | 3 | 2016 | 164 | 0.530 |
Why?
|
| Disease Models, Animal | 11 | 2025 | 4692 | 0.520 |
Why?
|
| Apoptosis | 1 | 2024 | 1863 | 0.520 |
Why?
|
| Neutropenia | 2 | 2017 | 205 | 0.510 |
Why?
|
| Outpatients | 3 | 2014 | 266 | 0.510 |
Why?
|
| Drug Monitoring | 5 | 2020 | 291 | 0.510 |
Why?
|
| Bacterial Load | 4 | 2025 | 33 | 0.510 |
Why?
|
| Gentamicins | 4 | 2017 | 86 | 0.500 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 282 | 0.490 |
Why?
|
| Pneumonia | 2 | 2017 | 341 | 0.490 |
Why?
|
| Virulence | 4 | 2022 | 271 | 0.470 |
Why?
|
| Gram-Positive Bacterial Infections | 5 | 2012 | 75 | 0.470 |
Why?
|
| Influenza, Human | 1 | 2022 | 703 | 0.470 |
Why?
|
| Serum | 5 | 2014 | 45 | 0.450 |
Why?
|
| Immunity, Innate | 1 | 2018 | 412 | 0.450 |
Why?
|
| Antimicrobial Stewardship | 1 | 2016 | 88 | 0.440 |
Why?
|
| APACHE | 4 | 2021 | 55 | 0.420 |
Why?
|
| Texas | 9 | 2024 | 3657 | 0.420 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17763 | 0.410 |
Why?
|
| Survival Analysis | 5 | 2018 | 1521 | 0.400 |
Why?
|
| Hyperglycemia | 1 | 2015 | 235 | 0.400 |
Why?
|
| Intensive Care Units | 5 | 2024 | 518 | 0.400 |
Why?
|
| Half-Life | 4 | 2023 | 151 | 0.400 |
Why?
|
| Urinary Tract Infections | 2 | 2016 | 331 | 0.400 |
Why?
|
| Aza Compounds | 2 | 2011 | 13 | 0.390 |
Why?
|
| Body Fluids | 1 | 2013 | 46 | 0.380 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2012 | 9 | 0.380 |
Why?
|
| Liposomes | 1 | 2013 | 201 | 0.370 |
Why?
|
| Enterococcus faecalis | 3 | 2022 | 50 | 0.370 |
Why?
|
| Cell Survival | 4 | 2024 | 849 | 0.370 |
Why?
|
| Mutation | 6 | 2012 | 6206 | 0.360 |
Why?
|
| Computer Simulation | 6 | 2018 | 681 | 0.360 |
Why?
|
| Cell Line | 4 | 2024 | 2591 | 0.360 |
Why?
|
| Cefazolin | 2 | 2024 | 20 | 0.350 |
Why?
|
| Protein Binding | 4 | 2019 | 1674 | 0.350 |
Why?
|
| HIV Infections | 2 | 2023 | 2042 | 0.340 |
Why?
|
| Aerosols | 1 | 2011 | 59 | 0.340 |
Why?
|
| Escherichia coli Infections | 2 | 2012 | 196 | 0.340 |
Why?
|
| Staphylococcal Infections | 2 | 2024 | 566 | 0.340 |
Why?
|
| Treatment Outcome | 13 | 2018 | 13017 | 0.340 |
Why?
|
| Critical Illness | 3 | 2020 | 616 | 0.330 |
Why?
|
| Rec A Recombinases | 1 | 2010 | 27 | 0.330 |
Why?
|
| Prospective Studies | 11 | 2018 | 6544 | 0.330 |
Why?
|
| Polymerase Chain Reaction | 6 | 2012 | 1488 | 0.320 |
Why?
|
| Drug Synergism | 4 | 2019 | 239 | 0.320 |
Why?
|
| Sodium Chloride | 1 | 2010 | 91 | 0.320 |
Why?
|
| Larva | 2 | 2023 | 251 | 0.320 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2014 | 330 | 0.310 |
Why?
|
| Endocarditis, Bacterial | 3 | 2017 | 132 | 0.310 |
Why?
|
| Doxycycline | 2 | 2022 | 112 | 0.300 |
Why?
|
| Kinetics | 5 | 2017 | 1093 | 0.300 |
Why?
|
| Neutrophils | 1 | 2011 | 371 | 0.290 |
Why?
|
| ADP Ribose Transferases | 1 | 2008 | 20 | 0.290 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2008 | 8 | 0.290 |
Why?
|
| Selection, Genetic | 1 | 2009 | 157 | 0.290 |
Why?
|
| Cohort Studies | 7 | 2024 | 5124 | 0.290 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2008 | 43 | 0.280 |
Why?
|
| Bacterial Adhesion | 1 | 2008 | 104 | 0.280 |
Why?
|
| Transcription Factors | 1 | 2018 | 2462 | 0.280 |
Why?
|
| Clarithromycin | 1 | 2008 | 130 | 0.280 |
Why?
|
| Gram-Negative Aerobic Bacteria | 1 | 2007 | 1 | 0.270 |
Why?
|
| Monte Carlo Method | 7 | 2014 | 102 | 0.270 |
Why?
|
| Biofilms | 1 | 2008 | 95 | 0.270 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 170 | 0.270 |
Why?
|
| Drug Resistance, Microbial | 5 | 2011 | 196 | 0.270 |
Why?
|
| Rifampin | 1 | 2008 | 122 | 0.270 |
Why?
|
| Tetracyclines | 2 | 2017 | 19 | 0.260 |
Why?
|
| Risk Factors | 10 | 2019 | 11034 | 0.260 |
Why?
|
| Streptococcus pneumoniae | 2 | 2006 | 389 | 0.260 |
Why?
|
| Energy Metabolism | 1 | 2012 | 795 | 0.250 |
Why?
|
| Prevalence | 6 | 2024 | 2706 | 0.250 |
Why?
|
| Injections, Subcutaneous | 2 | 2020 | 134 | 0.250 |
Why?
|
| Sulbactam | 1 | 2025 | 6 | 0.240 |
Why?
|
| Meningitis, Bacterial | 1 | 2006 | 98 | 0.230 |
Why?
|
| DNA Topoisomerase IV | 3 | 2012 | 10 | 0.230 |
Why?
|
| DNA Gyrase | 3 | 2012 | 26 | 0.230 |
Why?
|
| Risk Assessment | 4 | 2016 | 3721 | 0.230 |
Why?
|
| Tobramycin | 1 | 2004 | 22 | 0.220 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 2994 | 0.220 |
Why?
|
| Antiviral Agents | 2 | 2015 | 813 | 0.220 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2024 | 61 | 0.210 |
Why?
|
| Pyridones | 1 | 2025 | 149 | 0.210 |
Why?
|
| Biomarkers | 4 | 2018 | 3426 | 0.210 |
Why?
|
| Liver | 3 | 2021 | 1805 | 0.210 |
Why?
|
| Flavonoids | 3 | 2012 | 83 | 0.200 |
Why?
|
| Immunocompromised Host | 3 | 2017 | 312 | 0.200 |
Why?
|
| Ribavirin | 1 | 2003 | 86 | 0.200 |
Why?
|
| Drug Costs | 2 | 2016 | 63 | 0.200 |
Why?
|
| Injections, Intravenous | 3 | 2015 | 241 | 0.200 |
Why?
|
| Communicable Diseases | 3 | 2010 | 158 | 0.200 |
Why?
|
| Iron Chelating Agents | 1 | 2023 | 14 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 568 | 0.190 |
Why?
|
| Salmonella Infections | 1 | 2023 | 31 | 0.190 |
Why?
|
| Multilocus Sequence Typing | 1 | 2022 | 63 | 0.190 |
Why?
|
| Models, Animal | 2 | 2023 | 460 | 0.190 |
Why?
|
| Eicosanoids | 1 | 2022 | 13 | 0.190 |
Why?
|
| Tissue Distribution | 3 | 2015 | 367 | 0.190 |
Why?
|
| PPAR alpha | 1 | 2022 | 53 | 0.180 |
Why?
|
| Oils, Volatile | 1 | 2022 | 5 | 0.180 |
Why?
|
| Arthritis | 1 | 2023 | 85 | 0.180 |
Why?
|
| Immune Tolerance | 2 | 2021 | 153 | 0.180 |
Why?
|
| Phytochemicals | 1 | 2021 | 10 | 0.180 |
Why?
|
| Metabolic Clearance Rate | 3 | 2015 | 132 | 0.170 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1706 | 0.170 |
Why?
|
| Virginiamycin | 1 | 2001 | 2 | 0.170 |
Why?
|
| Cell Plasticity | 1 | 2021 | 39 | 0.170 |
Why?
|
| Phenols | 1 | 2021 | 71 | 0.170 |
Why?
|
| Research Design | 2 | 2013 | 718 | 0.170 |
Why?
|
| Decision Making | 1 | 2006 | 692 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 3 | 2018 | 985 | 0.160 |
Why?
|
| Population Surveillance | 1 | 2003 | 396 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2022 | 451 | 0.160 |
Why?
|
| Home Infusion Therapy | 1 | 1999 | 6 | 0.160 |
Why?
|
| Education, Medical | 1 | 2024 | 293 | 0.160 |
Why?
|
| Mitochondria | 1 | 2025 | 774 | 0.150 |
Why?
|
| Young Adult | 6 | 2016 | 10126 | 0.150 |
Why?
|
| Mouth Neoplasms | 1 | 2020 | 98 | 0.150 |
Why?
|
| Oxidative Stress | 1 | 2024 | 812 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2021 | 287 | 0.150 |
Why?
|
| Body Weight | 2 | 2020 | 992 | 0.150 |
Why?
|
| Quinolones | 4 | 2017 | 58 | 0.150 |
Why?
|
| Microsomes, Liver | 3 | 2009 | 96 | 0.150 |
Why?
|
| Penicillanic Acid | 2 | 2009 | 10 | 0.150 |
Why?
|
| Adolescent | 8 | 2016 | 21018 | 0.140 |
Why?
|
| Gene Expression | 3 | 2019 | 1508 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2022 | 293 | 0.140 |
Why?
|
| Cytochrome b Group | 1 | 2018 | 5 | 0.140 |
Why?
|
| Lepidoptera | 1 | 2018 | 4 | 0.140 |
Why?
|
| Microsomes | 2 | 2009 | 37 | 0.140 |
Why?
|
| Intestinal Mucosa | 3 | 2009 | 767 | 0.140 |
Why?
|
| Proteomics | 1 | 2022 | 612 | 0.140 |
Why?
|
| Asia | 1 | 2018 | 125 | 0.130 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.130 |
Why?
|
| Francisella tularensis | 1 | 2017 | 16 | 0.130 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 1140 | 0.130 |
Why?
|
| Maleates | 1 | 2017 | 11 | 0.130 |
Why?
|
| Microdialysis | 1 | 2017 | 59 | 0.130 |
Why?
|
| Microbiota | 1 | 2023 | 449 | 0.130 |
Why?
|
| United States | 4 | 2018 | 11867 | 0.130 |
Why?
|
| Physicians | 1 | 2024 | 637 | 0.130 |
Why?
|
| Daptomycin | 2 | 2017 | 17 | 0.130 |
Why?
|
| Arginine | 1 | 2019 | 336 | 0.120 |
Why?
|
| Nicotinic Antagonists | 1 | 2016 | 8 | 0.120 |
Why?
|
| Carbimazole | 1 | 2016 | 1 | 0.120 |
Why?
|
| Methimazole | 1 | 2016 | 3 | 0.120 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2007 | 256 | 0.120 |
Why?
|
| Sucrose | 1 | 2016 | 36 | 0.120 |
Why?
|
| Antithyroid Agents | 1 | 2016 | 4 | 0.120 |
Why?
|
| Endocarditis | 1 | 2017 | 105 | 0.120 |
Why?
|
| Agranulocytosis | 1 | 2016 | 12 | 0.120 |
Why?
|
| Inflammation | 2 | 2023 | 1503 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2016 | 33 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 4734 | 0.120 |
Why?
|
| HLA-B Antigens | 1 | 2016 | 30 | 0.120 |
Why?
|
| Organophosphonates | 1 | 2015 | 21 | 0.120 |
Why?
|
| Comorbidity | 1 | 2021 | 1609 | 0.120 |
Why?
|
| Cytosine | 1 | 2015 | 58 | 0.120 |
Why?
|
| Food Preferences | 1 | 2016 | 114 | 0.110 |
Why?
|
| Population | 2 | 2006 | 22 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 739 | 0.110 |
Why?
|
| Adenoviridae Infections | 1 | 2015 | 76 | 0.110 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2015 | 17 | 0.110 |
Why?
|
| Intervertebral Disc | 1 | 2015 | 13 | 0.110 |
Why?
|
| Cystitis | 1 | 2015 | 48 | 0.110 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 31 | 0.110 |
Why?
|
| Aspergillosis | 2 | 2006 | 46 | 0.110 |
Why?
|
| Lung Diseases, Fungal | 2 | 2006 | 37 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 495 | 0.110 |
Why?
|
| Singapore | 3 | 2010 | 16 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 836 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 761 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 321 | 0.110 |
Why?
|
| Genomics | 1 | 2022 | 1633 | 0.110 |
Why?
|
| Arginine Vasopressin | 1 | 2014 | 25 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 293 | 0.110 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 73 | 0.110 |
Why?
|
| Glucuronosyltransferase | 3 | 2013 | 64 | 0.100 |
Why?
|
| Dopamine | 1 | 2015 | 256 | 0.100 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 92 | 0.100 |
Why?
|
| Urine | 1 | 2014 | 92 | 0.100 |
Why?
|
| In Vitro Techniques | 3 | 2006 | 817 | 0.100 |
Why?
|
| Acclimatization | 1 | 2013 | 21 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 227 | 0.100 |
Why?
|
| Liver Regeneration | 1 | 2013 | 39 | 0.100 |
Why?
|
| Altitude | 1 | 2013 | 23 | 0.100 |
Why?
|
| Mitochondria, Liver | 1 | 2013 | 37 | 0.100 |
Why?
|
| Bacterial Typing Techniques | 1 | 2013 | 101 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 299 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8613 | 0.100 |
Why?
|
| Length of Stay | 2 | 2010 | 1403 | 0.100 |
Why?
|
| Infant, Premature | 2 | 2015 | 859 | 0.100 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 96 | 0.100 |
Why?
|
| Incidence | 2 | 2019 | 3357 | 0.100 |
Why?
|
| Antifungal Agents | 2 | 2006 | 297 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 22 | 0.090 |
Why?
|
| Risk | 1 | 2014 | 739 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 85 | 0.090 |
Why?
|
| Membranes, Artificial | 1 | 2012 | 27 | 0.090 |
Why?
|
| Glucuronides | 2 | 2009 | 29 | 0.090 |
Why?
|
| Rats, Wistar | 3 | 2021 | 309 | 0.090 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2011 | 46 | 0.090 |
Why?
|
| Rodent Diseases | 1 | 2011 | 15 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2007 | 1024 | 0.090 |
Why?
|
| Dogs | 1 | 2012 | 623 | 0.090 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2012 | 70 | 0.090 |
Why?
|
| Bordetella bronchiseptica | 1 | 2010 | 2 | 0.080 |
Why?
|
| Excipients | 1 | 2010 | 13 | 0.080 |
Why?
|
| Pharmaceutical Solutions | 1 | 2010 | 10 | 0.080 |
Why?
|
| Drug Antagonism | 2 | 2008 | 13 | 0.080 |
Why?
|
| Refrigeration | 1 | 2010 | 10 | 0.080 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 192 | 0.080 |
Why?
|
| Drug Storage | 1 | 2010 | 18 | 0.080 |
Why?
|
| Drug Stability | 1 | 2010 | 57 | 0.080 |
Why?
|
| Swine | 1 | 2014 | 1188 | 0.080 |
Why?
|
| Drug Contamination | 1 | 2010 | 36 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 853 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2011 | 364 | 0.080 |
Why?
|
| Flavanones | 1 | 2009 | 10 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 92 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 210 | 0.080 |
Why?
|
| Interleukin-8 | 1 | 2010 | 207 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 2323 | 0.080 |
Why?
|
| Drug Design | 1 | 2011 | 164 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 665 | 0.080 |
Why?
|
| Temperature | 1 | 2010 | 290 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 362 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 533 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1081 | 0.080 |
Why?
|
| Isoflavones | 2 | 2006 | 42 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2010 | 352 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 440 | 0.070 |
Why?
|
| Random Allocation | 1 | 2010 | 423 | 0.070 |
Why?
|
| Ampicillin | 2 | 2017 | 59 | 0.070 |
Why?
|
| Colorimetry | 1 | 2008 | 17 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2008 | 956 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2012 | 773 | 0.070 |
Why?
|
| Biomass | 1 | 2008 | 26 | 0.070 |
Why?
|
| Blotting, Southern | 1 | 2008 | 209 | 0.070 |
Why?
|
| Peer Review | 1 | 2008 | 36 | 0.070 |
Why?
|
| Publications | 1 | 2008 | 36 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 433 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1307 | 0.070 |
Why?
|
| Vancomycin Resistance | 2 | 2012 | 22 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2008 | 272 | 0.070 |
Why?
|
| Respiratory System | 1 | 2008 | 96 | 0.070 |
Why?
|
| Algorithms | 2 | 2005 | 1690 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 310 | 0.070 |
Why?
|
| Phenotype | 3 | 2015 | 4550 | 0.070 |
Why?
|
| Isoelectric Focusing | 1 | 2007 | 22 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2014 | 772 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2007 | 43 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 806 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2007 | 91 | 0.060 |
Why?
|
| DNA Fingerprinting | 1 | 2007 | 108 | 0.060 |
Why?
|
| Injections, Intraventricular | 1 | 2006 | 53 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1221 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2010 | 1746 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1270 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2010 | 401 | 0.060 |
Why?
|
| Logistic Models | 2 | 2008 | 1838 | 0.060 |
Why?
|
| Escherichia coli Proteins | 1 | 2009 | 310 | 0.060 |
Why?
|
| PubMed | 1 | 2006 | 22 | 0.060 |
Why?
|
| Stochastic Processes | 1 | 2006 | 34 | 0.060 |
Why?
|
| Catheter-Related Infections | 1 | 2008 | 137 | 0.060 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2007 | 117 | 0.060 |
Why?
|
| Injections, Spinal | 1 | 2006 | 133 | 0.060 |
Why?
|
| Sample Size | 1 | 2006 | 86 | 0.060 |
Why?
|
| Sternum | 1 | 2006 | 50 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 2102 | 0.060 |
Why?
|
| Deoxycholic Acid | 1 | 2006 | 14 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2007 | 422 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 776 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 2873 | 0.060 |
Why?
|
| Ventriculostomy | 1 | 2006 | 46 | 0.060 |
Why?
|
| Prognosis | 2 | 2014 | 4965 | 0.060 |
Why?
|
| Point Mutation | 1 | 2007 | 339 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2006 | 90 | 0.060 |
Why?
|
| Population Dynamics | 1 | 2005 | 29 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2008 | 1235 | 0.060 |
Why?
|
| Porins | 1 | 2005 | 38 | 0.060 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2005 | 60 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2025 | 135 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 1019 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2025 | 316 | 0.060 |
Why?
|
| Infection Control | 1 | 2006 | 162 | 0.060 |
Why?
|
| Colombia | 1 | 2024 | 50 | 0.050 |
Why?
|
| Aspergillus fumigatus | 1 | 2004 | 43 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 46 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1235 | 0.050 |
Why?
|
| Genotype | 1 | 2010 | 2654 | 0.050 |
Why?
|
| Monobactams | 1 | 2023 | 6 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 270 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2004 | 241 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 75 | 0.050 |
Why?
|
| Nose | 1 | 2024 | 112 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 230 | 0.050 |
Why?
|
| Biological Availability | 1 | 2003 | 140 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 545 | 0.050 |
Why?
|
| Carbon Isotopes | 1 | 2003 | 231 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3458 | 0.050 |
Why?
|
| Amyloidogenic Proteins | 1 | 2023 | 7 | 0.050 |
Why?
|
| Bacteroidetes | 1 | 2023 | 23 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2008 | 1074 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 431 | 0.050 |
Why?
|
| Immunity, Mucosal | 1 | 2023 | 90 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 362 | 0.050 |
Why?
|
| Enterococcus | 1 | 2002 | 30 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2002 | 99 | 0.050 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 231 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 239 | 0.050 |
Why?
|
| Emulsions | 1 | 2022 | 70 | 0.040 |
Why?
|
| Solubility | 1 | 2022 | 117 | 0.040 |
Why?
|
| Rhodococcus equi | 1 | 2001 | 7 | 0.040 |
Why?
|
| Particle Size | 1 | 2022 | 137 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2004 | 1476 | 0.040 |
Why?
|
| Actinomycetales Infections | 1 | 2001 | 14 | 0.040 |
Why?
|
| Veillonella | 1 | 2020 | 1 | 0.040 |
Why?
|
| Burkholderiaceae | 1 | 2020 | 1 | 0.040 |
Why?
|
| Neisseria | 1 | 2020 | 4 | 0.040 |
Why?
|
| Micrococcaceae | 1 | 2020 | 4 | 0.040 |
Why?
|
| Porphyromonas gingivalis | 1 | 2020 | 6 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2003 | 285 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2001 | 133 | 0.040 |
Why?
|
| Fusobacterium nucleatum | 1 | 2020 | 19 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 215 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 388 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 117 | 0.040 |
Why?
|
| Community Health Nursing | 1 | 1999 | 4 | 0.040 |
Why?
|
| Penicillins | 1 | 2000 | 154 | 0.040 |
Why?
|
| Neoplasms | 1 | 2014 | 2968 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3439 | 0.040 |
Why?
|
| Infant | 2 | 2014 | 13355 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2016 | 408 | 0.040 |
Why?
|
| Vietnam | 1 | 2019 | 66 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 2019 | 12 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 2658 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 711 | 0.040 |
Why?
|
| CD40 Antigens | 1 | 2019 | 25 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 788 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 121 | 0.040 |
Why?
|
| Software | 1 | 2003 | 754 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2021 | 4699 | 0.030 |
Why?
|
| Nafcillin | 1 | 2017 | 13 | 0.030 |
Why?
|
| Methicillin | 1 | 2017 | 43 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2017 | 82 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1175 | 0.030 |
Why?
|
| Data Collection | 1 | 1999 | 372 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2019 | 177 | 0.030 |
Why?
|
| Glycopeptides | 1 | 2017 | 26 | 0.030 |
Why?
|
| Genistein | 2 | 2007 | 39 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 632 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 250 | 0.030 |
Why?
|
| Azocines | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2016 | 8 | 0.030 |
Why?
|
| Quinolizines | 1 | 2016 | 7 | 0.030 |
Why?
|
| Varenicline | 1 | 2016 | 12 | 0.030 |
Why?
|
| Propylthiouracil | 1 | 2016 | 9 | 0.030 |
Why?
|
| Alkaloids | 1 | 2016 | 36 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 2015 | 32 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 2016 | 57 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 152 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2007 | 555 | 0.030 |
Why?
|
| Intestinal Absorption | 2 | 2006 | 170 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 6 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2015 | 14 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 2016 | 121 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 716 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2015 | 42 | 0.030 |
Why?
|
| Alginates | 1 | 2015 | 23 | 0.030 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2014 | 6 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 318 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 120 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 133 | 0.030 |
Why?
|
| Macrophages | 1 | 2019 | 664 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2014 | 74 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2014 | 83 | 0.030 |
Why?
|
| Acid Phosphatase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Ornithine Decarboxylase | 1 | 2013 | 18 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 166 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 277 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 230 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 678 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 49 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 231 | 0.030 |
Why?
|
| Maxillofacial Prosthesis | 1 | 1992 | 1 | 0.020 |
Why?
|
| Bilirubin | 1 | 2013 | 127 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2013 | 130 | 0.020 |
Why?
|
| Silicone Elastomers | 1 | 1992 | 23 | 0.020 |
Why?
|
| Adhesives | 1 | 1992 | 9 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2013 | 125 | 0.020 |
Why?
|
| Hospitalization | 2 | 2012 | 1943 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2012 | 64 | 0.020 |
Why?
|
| Cost Control | 1 | 2011 | 23 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2011 | 26 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2011 | 44 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1851 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2012 | 82 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1950 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 243 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 713 | 0.020 |
Why?
|
| Inpatients | 1 | 2014 | 544 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3858 | 0.020 |
Why?
|
| Propionates | 1 | 2009 | 35 | 0.020 |
Why?
|
| Leukotriene Antagonists | 1 | 2009 | 16 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2009 | 20 | 0.020 |
Why?
|
| Estradiol | 1 | 2012 | 482 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2010 | 51 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 444 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2009 | 54 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2947 | 0.020 |
Why?
|
| Biological Transport | 1 | 2009 | 333 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 751 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 3096 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2144 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 192 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 634 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1847 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2014 | 15103 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2012 | 558 | 0.020 |
Why?
|
| Apigenin | 1 | 2007 | 9 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2007 | 87 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 137 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1399 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 231 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1484 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 2006 | 199 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 193 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 421 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 181 | 0.010 |
Why?
|
| DNA, Fungal | 1 | 2006 | 77 | 0.010 |
Why?
|
| Subcutaneous Tissue | 1 | 2005 | 14 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2005 | 78 | 0.010 |
Why?
|
| Intestines | 1 | 2009 | 592 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2011 | 561 | 0.010 |
Why?
|
| Perfusion | 1 | 2006 | 212 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 5283 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 66 | 0.010 |
Why?
|
| Lipopeptides | 1 | 2004 | 35 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2012 | 2488 | 0.010 |
Why?
|
| Echinocandins | 1 | 2004 | 42 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 3714 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 693 | 0.010 |
Why?
|
| Pneumococcal Infections | 1 | 2006 | 279 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2003 | 56 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2003 | 140 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1406 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 517 | 0.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2006 | 440 | 0.010 |
Why?
|
| Trauma Centers | 1 | 2002 | 209 | 0.010 |
Why?
|
| Child | 1 | 2014 | 26383 | 0.010 |
Why?
|
| Rotation | 1 | 1992 | 40 | 0.010 |
Why?
|
| Tensile Strength | 1 | 1992 | 47 | 0.010 |
Why?
|
| Surface Properties | 1 | 1992 | 82 | 0.010 |
Why?
|
| Materials Testing | 1 | 1992 | 81 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 1992 | 179 | 0.010 |
Why?
|
| Skin | 1 | 1992 | 553 | 0.000 |
Why?
|